Business context and reporting period
This is Proteon Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2014; the filing does not identify Protara Therapeutics as the registrant. Proteon was a clinical-stage biopharmaceutical company developing PRT-201 for vascular access failure in hemodialysis patients. It had no product sales. Share and per-share amounts reflect the 1-for-15.87 reverse stock split effective October 6, 2014.
Financial performance and liquidity
Unless otherwise stated, amounts below are in millions of dollars. The filing’s financial statements report amounts in thousands.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $2.948 | $0 | $2.948 | $0 |
| Research and development | $1.773 | $0.971 | $4.558 | $2.974 |
| General and administrative | $1.041 | $0.943 | $2.697 | $2.360 |
| Operating income (loss) | $0.134 | ($1.914) | ($4.307) | ($5.334) |
| Net loss | ($5.181) | ($2.103) | ($10.575) | ($5.515) |
Q3 operating income reflected one-time revenue, not product sales. Q3 net loss included $5.325 million of other expense, principally a fair-value remeasurement of Series D investor rights. For the nine months, net loss attributable to common stockholders was $16.261 million, including $5.686 million of preferred-stock accretion.
- Cash and investments: $21.686 million at September 30, 2014, versus $5.152 million at December 31, 2013. Current assets were $21.920 million and current liabilities $2.658 million.
- Cash flows, nine months: operating activities used $7.940 million; investing activities used $16.162 million, mainly reflecting purchases of available-for-sale investments; financing activities provided $24.548 million. Cash increased by $0.446 million.
- Debt and capital: Convertible notes, including accrued interest, converted into Series D preferred stock in May 2014; no convertible notes remained at quarter-end. The balance sheet reported an $11.903 million non-current investor-rights liability and $126.169 million of redeemable convertible preferred stock.
- Subsequent IPO: The company completed sales of 7,026,500 common shares at $10 per share by November 21, 2014, for approximately $62.5 million net proceeds. Preferred shares converted into common stock at the IPO. The filing says less than $1 million of IPO proceeds had been used as of November 24.
Material changes versus the prior comparable period
- Revenue increased by $2.948 million in 2014 from zero in 2013 because residual rights under a 2009 pharmaceutical-company option agreement lapsed in August and deferred revenue was recognized.
- Nine-month R&D expense rose $1.584 million, primarily from Phase 3 clinical-trial and related manufacturing costs; G&A rose $0.337 million.
- Nine-month net loss increased $5.060 million, driven principally by the $5.3 million investor-rights fair-value expense and higher operating costs.
- Nine-month operating cash use increased to $7.940 million from $4.909 million, while the Series D financing provided $25 million gross proceeds and notes conversion added approximately $4.6 million of noncash preferred-stock issuance.
Outlook, commentary and risks
- The first Phase 3 trial of PRT-201 in radiocephalic AVFs began in Q3 2014; management expected to start the second trial in the first half of 2015. Management estimated cash and investments plus IPO proceeds would fund operations into 2018. However, the risk discussion states those resources were not expected to fund completion of the second Phase 3 trial.
- The company expected increasing operating losses as it advanced clinical development and public-company operations. Product revenue depended on successful trials, regulatory approval and commercialization, all uncertain.
- Management disclosed that the Phase 2 primary efficacy endpoint did not show statistically significant benefit for the 30-microgram dose versus placebo. Favorable radiocephalic-AVF subgroup findings were not prespecified; the company cautioned that they might not be replicated in Phase 3.
- Key risks include trial enrollment, efficacy and safety outcomes, regulatory delays, dependence on contract manufacturers and CROs, financing needs, intellectual-property claims, and future market access and reimbursement. One finished-product supplier had received an FDA warning letter; the FDA separately stated that the warning did not affect the batch intended for Phase 3.
- The company reported no material legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of September 30, 2014. It reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Confirm the registrant identity: the supplied filing is for Proteon Therapeutics, Inc., not Protara Therapeutics, Inc.
- Review the IPO proceeds, post-quarter preferred-stock conversion, and resulting capitalization and dilution.
- Track Phase 3 enrollment, timing, endpoints and results, particularly given the non-significant Phase 2 primary endpoint and post-hoc subgroup analysis.
- Reconcile the runway statements: funding was estimated to last into 2018, but the filing also said it would not fund completion of the second Phase 3 trial.
- Check the accumulated-deficit amount: the balance sheet and note report approximately $116.5 million, while a risk-factor passage states $106.5 million.
- Assess the recurring cash burn separately from the one-time $2.948 million revenue and noncash fair-value expense.